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Objectives: Cryptococcus neoformans is an opportunistic fungus that causes fatal
meningoencephalitis especially in AIDS patients. There is an increasing need for
discovery of new anti-cryptococcal drugs due to emergence of resistance cases in
recent years. In this study, we aim to elucidate the antifungal effect of triclosan against
C. neoformans.
Methods: Minimal inhibitory concentration (MIC) of triclosan in different C. neoformans
strains was first examined. The in vitro interactions between triclosan and two
standard anti-fungal drugs (amphotericin B and fluconazole) were further evaluated by
microdilution checkerboard assay. Mechanism of triclosan fungicidal activity was then
investigated by viewing the cell morphology under transmission electron microscope.
Results: We reported that triclosan potently inhibited the growth of C. neoformans.
A combination of triclosan with amphotericin B or with fluconazole enhanced their
fungicidal effects. Triclosan-treated C. neoformans displayed characteristics such as
nuclear chromatin condensation, extensive intracellular vacuolation and mitochondrial
swelling, indicating that triclosan triggered apoptosis-like cell death.
Conclusion: In summary, our report suggests triclosan as an independent drug or
synergent for C. neoformans treatment.
Keywords: antifungal effect, amphotericin B, apoptosis, Cryptococcus neoformans, fluconazole, synergy,
triclosan
INTRODUCTION
Infection by Cryptococcus neoformans has become a major cause of mortality following the
increased numbers of AIDS patients (Mitchell and Perfect, 1995; Pancharoen et al., 2001) and
is estimated to cause approximately 600,000 deaths worldwide annually (Park et al., 2009).
C. neoformans exists ubiquitously in the environment, commonly found in decaying wood and
bird excreta (Lazera et al., 1996). Most individuals are exposed to C. neoformans through inhalation
from the environment during their childhood but stay asymptomatic (Goldman et al., 2001)
Frontiers in Microbiology | www.frontiersin.org 1 March 2016 | Volume 7 | Article 360
fmicb-07-00360 March 17, 2016 Time: 16:29 # 2
Movahed et al. Triclosan “Inhibits” Cryptococcus neoformans
because C. neoformans is an opportunistic pathogen which rarely
progresses to disease in immune competent individuals.
However, it can result in life-threatening infection in
immunosuppressed or immunocompromised patients (Coelho
et al., 2014). Infection of C. neoformans in lung leads to
cryptococcal pneumonia whereas systemic dissemination often
causes fatal meningoencephalitis (Lin and Heitman, 2006).
In recent years, the widespread use of anti-microbial drugs in
the treatment of fungal infection has led to the global emergence
of resistant fungal strains. Numerous fungal pathogens including
C. neoformans have demonstrated increasing resistance to
common antifungal drugs such as amphotericin B and
fluconazole (Perfect and Cox, 1999). A recent global study
of nearly three thousand C. neoformans isolates shows that
>11% of the isolates are resistant to fluconazole (Pfaller et al.,
2009). Fluconazole-heteroresistant phenotype of C. neoformans
has also been detected in a significant proportion of clinical
isolates (Yamazumi et al., 2003). Increased drug resistance in
fungal species is mainly attributed to overexpression and hotspot
mutations of genes that encode for eﬄux ATP-binding cassette
(ABC) transporters (Sanglard et al., 1995; Looi et al., 2005) such
as CDR1, CDR2, and MDR1 (Fling et al., 1991; Prasad et al., 1995;
Sanglard et al., 1997). Changes in fungal cell phospholipids and
membrane sterol composition can also reduce drug permeation
ability (Hitchcock et al., 1986). Alternate usage of other enzymes
in the same biosynthetic pathway as a substitute for the drug-
targeted enzyme also confers resilience and endurance to the
yeasts (Howell et al., 1990). Therefore, studies to discover new
drugs or combination of multiple anti-microbial drugs are
essential. Some drug combinations demonstrate synergistic effect
and superiority to the currently available therapies (Mukherjee
et al., 2005; Munoz et al., 2006). For instance, combinational
usage of fluconazole plus amphotericin B adds benefit in
candidemia treatment (Odds, 2003a).
Triclosan (2,4,4′-trichloro-2′-hydroxydiphenylether, C12H17
Cl3O2) is a chlorinated compound which is widely used for
personal care products such as soap, toothpaste and plastics in
domestic as well as healthcare settings due to its safety, efficiency
and long-lasting effects (Jones et al., 2000). Importantly, various
studies using different test systems indicate that triclosan is a
non-mutagenic and non-genotoxic agent (Fang et al., 2010). The
drug is able to persist for at least 0.7 h (Loftsson et al., 1999)
in human fluids, including nasal secretion, serum, urine, and
milk after exposure (Syed et al., 2014). Triclosan demonstrates
broad-spectrum anti-microbial properties against various species
of microorganisms with MICs ranging from 0.1 to 30 mg/l
(Schweizer, 2001) including Candida species (Vischer and Regos,
1974; Regos et al., 1979). Previous studies suggest that triclosan
likely perturbs cell structure and results in loss of permeability-
barrier function (Villalain et al., 2001). It inhibits bacterial
and fungal fatty acid synthetic enzyme, by targeting Fab1–
encoding NADH-dependent enoyl-acyl-carrier protein reductase
(McMurry et al., 1998; Heath et al., 1999; Stewart et al., 1999).
Although the antifungal effect of triclosan has been reported in
Candida albicans and several fungal species (Vischer and Regos,
1974; Regos et al., 1979; Yu et al., 2011), at present, the effect
of triclosan in C. neoformans has not been investigated. In this
study, the inhibitory effect of triclosan as well as the fungicidal
synergism between triclosan and standard antifungal drugs
against C. neoformans were evaluated. In addition, we examined
the mechanism of antifungal action by viewing triclosan-treated
cells under electron microscopy.
MATERIALS AND METHODS
Fungal Isolates and Chemicals
Cryptococcus neoformans H99, C. albicans 90028 and C. albicans
SC5314 (MYA2876) were obtained from American Type Culture
Collection (ATCC). C. neoformans C14 and C17 strains were
isolated from inpatients at the University of Malaya Medical
Center. C. neoformans H4, S48B, and S68B environmental strains
were isolated from bird droppings at different locations in Klang
valley, Malaysia (Tay et al., 2005). All C. neoformans strains used
were C. neoformans var. grubii, the predominant serotype A,
genotype VNI with an α-mating type (Tay et al., 2006).
Amphotericin B, fluconazole, and triclosan were purchased
from Sigma–Aldrich (St. Louis, MO, USA). Stock solutions were
prepared at 10 mg/ml by dissolving the amphotericin B and
triclosan powder in Dimethyl sulfoxide (DMSO), and fluconazole
in water. Drugs were stored at−20◦C until use.
Disk Diffusion Assay
Five single colonies were picked and inoculated into Sabouraud
dextrose broth (SDB). Cells were grown overnight in a rotary
shaker at 200 rpm at 35◦C. An aliquot of 100 µl of the
yeast suspension at 106 CFU/ml was prepared, applied onto
the Sabouraud dextrose agar (SDA) plate and spread uniformly
using a cotton swab. Then, 6-mm paper disks impregnated with
different concentrations of triclosan (3.125, 6.25, 12.5, 25, 50,
and 100 µg) were positioned on a C. neoformans H99 agar
plate to evaluate the antifungal effect of triclosan. In the synergy
test, 25 µg of a drug alone or in combination were placed
onto the agar surface. The synergy test was repeated using sub-
inhibitory concentrations of 6.25 µg/ml from AMB and FLU
alone and in combination with 6.25, 3.125, and 1.56 µg/ml
of triclosan. Dimethyl sulfoxide (DMSO) was used as negative
control. After incubation at 37◦C for 48 h, the diameters of the
growth inhibition zone were measured.
Broth Microdilution Assay
The drug minimum inhibition concentration (MIC) was
determined by broth microdilution assay according to Clinical
and Laboratory Standards Institute (CLSI) standard (Clinical and
Laboratory Standards Institute [CLSI], 2008). The inoculum was
prepared by picking five colonies (∼1 mm diameter) from a
fresh culture plate. Colonies were resuspended in 2 ml distilled
water and vortexed for 15 s. The cell density was adjusted to 75%
transmittance at 530 nm wavelength using a spectrophotometer.
A working suspension was made by a 1:50 dilution followed by a
1:10 dilution of the stock suspension with RPMI 1640 medium
supplemented with 34.53 mg/ml morpholinepropanesulfonic
acid (MOPS) at pH 7.0 to yield yeast stock suspension of
1.0 to 5.0 × 103 cells/ml. Antifungal drugs, amphotericin B
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(32 to 0.017 µg/ml), fluconazole (128 to 0.068 µg/ml), and
triclosan (128 to 0.068 µg/ml) were serially diluted in 96-well flat-
bottomed microtiter plates. The cells suspension (100 µl) were
then seeded into the plate and incubated for 48 h. The microtiter
plates for C. albicans and C. neoformans were visually scored
after incubation at 37◦C for 24 and 48 h, respectively (Tay et al.,
2011). Each well was resuspended and agitated for 5 min, and
the optical density (OD) at 570 nm wavelength was determined
with a spectrophotometer. All samples were run in duplicate. The
MIC-1 was defined as the minimal concentration that resulted in
80% growth inhibition while MIC-2 was defined as the minimal
concentration that resulted in 50% of growth inhibition (Yu et al.,
2011).
Fungicidal Assay
The MFCs of triclosan was determined by conventional culture-
based CFU method from microtitration plate in duplicates, as
previously described (Meletiadis et al., 2007). Total amount of
20 and 100 µl from all visually clear wells and the first well
with the highest drug concentration showing growth (0.5x MIC)
were mixed by pipetting up and down several times, washed
and subcultured onto SDA plates in duplicates. The SDA plates
were incubated at 37◦C for 48 h, and the CFU were observed for
each drug concentration. The MFCs were defined as the lowest
drug concentration yielding no growth using 20 µl (CFU20
MFC) and 100 µl (CFU100 MFC). Triclosan was considered
fungicidal when the MFC/MIC ratio is ≤4 and fungistatic when
the MFC/MIC ratio is ≥4 (Pfaller et al., 2004; Meletiadis et al.,
2007).
Synergy Checkerboard Assay
Antibiotic interactions were evaluated using the checkerboard
assay as previously described (Rand et al., 1993). Checkerboards
were prepared by using serial dilutions of amphotericin B (0.004
to 4.0 µg/ml) and fluconazole (0.0156 to 16.0 µg/ml) in the
horizontal wells and triclosan (0.25 to 16.0 µg/ml) in the vertical
wells. A fungal suspension was prepared as described in broth
microdilution assay (approximately 5× 103 CFU/ml), and 100µl
was inoculated into each well of a 96-well microtiter plate.
Plates were read after 48 h of incubation at 35◦C, and the wells
without visible signs of growth were identified by placing the
plate on a mirrored surface. Each well was resuspended and
agitated for 5 min, and the OD at 570 nm wavelength was
determined with a spectrophotometer. The fractional inhibitory
concentration index (FICI) was calculated for each drug using
following formula: FICI = FIC (triclosan) + FIC (drug), where
FIC equals to MIC-2 of the drug in combination divided by
the MIC-2 of the drug alone. FICI ≤ 0.5 indicates synergy,
FICI > 4 indicates antagonism whereas 0.5 > FICI > 4 suggests
no interaction (additivity/indifference; Odds, 2003b).
Electron Microscopy
Yeast cells were pelleted by centrifugation and resuspended
in 5 ml of distilled water. The turbidity of the suspension
was adjusted with a spectrophotometer to 75% transmittance
at 530 nm. The distilled suspension was diluted 1:50 (0.1 ml
plus 4.9 ml) with RPMI 1640 medium. The cell suspension
was treated with 0.5 µg/ml of triclosan at 37◦C, for 2 h. Cells
were then collected and fixed with 4% glutaraldehyde fixative
for 120 min. Cells were washed few times with cacodylate
buffer and post fixed with OsO4:cacodylate buffer (1:1) for
2 h and kept in cacodylate buffer at 4◦C overnight. The
samples were washed with distilled water, incubated with uranyl
acetate for 10 min before another washing step. Dehydration
was performed using 35, 50, 75, and 95% (v/v) ethanol for
10 min each, and followed by 100% ethanol, 15 min for three
times. Samples were then incubated with propylene oxide:epon
(1:1) for 1 h, propylene oxide:epon (1:3) for 2 h and epon
for an overnight incubation. This was followed by embedding
the yeast pellet in resin for 5 h at 37◦C followed by 60◦C
overnight. Images were obtained using EFTEM LIBRA 120
transmission electron microscope (Carl Zeiss, Oberkochen,
Germany).
Apoptosis Assay
Cell apoptosis was examined by terminal deoxynucleotidyl
transferase (TdT)-mediated dUTP nick end labeling (TUNEL)
assay using FLOWTAC kit (Trevigen, Gaithersburg, MD, USA).
Log-phase cultured cells (107 cells) were treated with 2 mM
hydrogen peroxide (H2O2) or 0.5 µg/ml triclosan for 4 h at
37◦C. Cells were fixed in 1 ml 3.7% formaldehyde for 10 min
followed by CytoninTM permeabilization for 30 min. Cells were
then washed and resuspended in labeling reaction mix (TdT
dNTP mix, TdT enzyme, 1x Mn2+, 1x TdT labeling buffer) at
37◦C for 1 h. Reaction was stopped by adding 1x Stop Buffer
followed by staining with 25 µl Strep-Fluorescein for 10 min in
dark. Propidium iodide and RNase were added to the cells before
analyzed by a FACS Canto cytometer (BD Biosciences, Franklin
Lakes, NJ, USA).
Statistical Analysis
Data were analyzed with unpaired two-tailed Student’s t-test.
Samples were considered significant if P < 0.05.
RESULTS
Triclosan Inhibits the Growth of
C. neoformans
To evaluate the antifungal effect of triclosan, 6-mm paper disks
impregnated with different concentrations of triclosan (3.125,
6.25, 12.5, 25, 50, and 100µg) were positioned on a C. neoformans
H99 agar plate for an incubation period of 48 h. Control disk
(with DMSO) displayed no inhibitory zone. In contrast, we
noted that the diameters of the inhibition zones surrounding
the triclosan-impregnated disks increased steadily from 7 to
17.6 mm in a dose-dependent manner (Figure 1A). A linear
relationship was observed between the inhibition zone size and
Log concentration of triclosan (Figure 1B).
Triclosan MIC-1 and MIC-2 endpoint values, which represent
reduction of cell turbidity at 80 and 50%, respectively, were
measured by broth microdilution assay (Table 1). Triclosan was
fungicidal against C. neoformans H99, with MIC-1 = 3.80 and
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FIGURE 1 | Agar disk diffusion assay. (A) Paper disks impregnated with control DMSO or 3.125, 6.25, 12.5, 25, 50, and 100 µg of triclosan were placed on the
agar plate containing Cryptococcus neoformans. Diameters of the inhibition zone were measured after 48 h of incubation. Data shown is a representative picture of
three independent experiments. (B) Graph shows the inhibition diameter (mm) of C. neoformans plate after triclosan treatment. Data shown are mean ± SD.
∗P < 0.05, ∗∗P < 0.01.
TABLE 1 | Minimal inhibitory concentration-1 (80% inhibition) and MIC-2
(50% inhibition) readings of triclosan in different strains of Cryptococcus
neoformans and Candida albicans.
Fungal strains MIC-1 (µg/ml) MIC-2 (µg/ml)
Cryptococcus neoformans H99 3.80 2.70
Cryptococcus neoformans C14 5.197 2.130
Cryptococcus neoformans C17 4.875 2.280
Cryptococcus neoformans H4 1.14 0.54
Cryptococcus neoformans S48B 0.37 0.12
Cryptococcus neoformans S68B 0.25 0.08
Candida albicans 90028 59.6 44.0
Candida albicans SC5314 >64 33.8
Data are representative of three independent experiments.
MIC-2 = 2.70 µg/ml. Local clinical isolates of C. neoformans
tested (C14 and C17) showed MIC-1 at 5.197 and 4.875 µg/ml,
and MIC-2 at 2.130 and 2.280 µg/ml. Environmental strains
C. neoformans H4, S48B and S68B strains showed comparable
MIC-1 and MIC-2 values ranging from 0.25 to 1.14 µg/ml and
0.08 to 0.54 µg/ml, respectively (Table 1). Further, we showed
that the MIC-1 and MIC-2 of triclosan in two C. albicans (90028
and SC5314) strains were between 16 and 64 µg/ml, consistent
with a previous report (Yu et al., 2011). The relatively lower MIC
values in C. neoformans suggest that the triclosan is more potent
against C. neoformans compared to C. albicans.
A cell culture CFU-based fungicidal assay was then performed
to determine if the triclosan was fungicidal or fungistatic
(Table 2). CFU formation can be visualized in the wells
with low concentrations (≤0.5 µg/ml) but no CFU was
detected in the media recovered from the wells treated
with ≥1 µg/ml, indicating that MFC for C. neoformans
H99 was 1 µg/ml. Thus, our data suggest that triclosan
wasfungicidal (MFC/MIC-2 ratio= 0.37, ≤4).
TABLE 2 | CFU count.
Triclosan (µg/ml) CFU count
0.065 >300
0.125 177
0.25 163
0.5 96
1 0
2 0
Total CFU count in the cell culture CFU-based fungicidal assay. Data shown are
representative of two independent experiments.
Triclosan Demonstrates a Synergistic
Effect with Amphotericin B and
Fluconazole
In vitro interactions between triclosan and two standard
antifungal agents, amphotericin B and fluconazole were
examined using a disk diffusion assay (Figure 2). Inhibition zone
for amphotericin B treatment alone was 10 mm. Noticeably,
combinational usage of triclosan plus amphotericin B caused
enlargement of the inhibition zone to 17 mm (Figure 2A).
On the other hand, fluconazole treatment alone showed
incomplete inhibition zone of approximately 11 mm,
while the combinational usage of triclosan plus fluconazole
remarkably augmented the size of inhibition zone to 16 mm
(Figure 2B).
To further confirm the result, we repeated the experiment
using subinhibitory concentrations of drugs. Increasing
concentrations of triclosan at 1.56, 3.125, and 6.25 µg/ml were
applied on the paper disks containing 6.25 µg amphotericin
B (Figure 2C) or fluconazole (Figure 2D) and used for disk
diffusion assay. No or minimal inhibition zones were observed
in the absence of triclosan while addition of triclosan caused
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FIGURE 2 | The effect of triclosan with amphotericin B and fluconazole. (A,B) Agar disk diffusion assay for triclosan (TCS) in combination with
(A) amphotericin B (AMB), or (B) fluconazole (FLC) in C. neoformans H99-containing agar plates. 25 µg of each drug was applied on a disk. (C,D) Agar disk
diffusion assay for TCS (1.56, 3.125, and 6.25 µg/ml) in combination with at subinhibitory concentrations (6.25 µg/ml) of (C) AMB and (D) FLU. Diameters of the
inhibition zone were measured after 48 h of incubation. Asterisk ∗ indicates partial inhibition. Data shown are representative pictures of three independent
experiments. (E,F) Graphs show the inhibition diameter (mm) of C. neoformans plate after triclosan treatment in combination with AMB or FLU. X-axis shows Log
concentration of triclosan. Data shown are mean ± SD. ∗P < 0.05, ∗∗P < 0.01.
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TABLE 3 | Checkerboard assay.
MIC alone MIC combined FIC FICI Note
Amphotericin B 0.23 0.008 0.035 0.127 Synergy
Triclosan 2.7 0.25 0.092
Fluconazole 3.2 0.015 0.005 0.020 Synergy
Triclosan 2.7 0.06 0.022
Synergy effect of triclosan with amphotericin B or fluconazole in C. neoformans.
FICI ≤ 0.5 indicates synergistic effect. Data shown are representative of two
independent experiments.
enlargement of inhibition zone in a dose-dependent manner.
Both combinations of triclosan with amphotericin B or
fluconazole showed linear inhibition patterns (Figures 2E,F).
These results suggest that the effect of triclosan with the standard
drugs is either synergistic or additive.
The combinational effect of standard drugs and triclosan
was further assessed using checkerboard assay to define the
median FICI values (Table 3). Both combination of drugs, i.e.,
triclosan plus amphotericin B (FICI = 0.127), or triclosan plus
fluconazole (FICI = 0.020) showed a FICI value <0.5, indicating
the synergistic (but not additive) effect of triclosan with both
standard drugs.
Triclosan Triggers Apoptotic-Like Cell
Death in C. neoformans
To examine the inhibitory mechanism of triclosan on
C. neoformans, we processed the control and triclosan-
treated (2 h) cells for visualization under electron microscope.
Untreated C. neoformans showed an intact cell structure with
normal morphologies of nucleus and cytoplasm (Figures 3A,B).
In contrast, triclosan-treated C. neoformans demonstrated
disrupted cell morphologies including apparent mitochondrial
swelling and extensively enlarged cytoplasmic vacuolations
(Figures 3C–F). Nuclear chromatin condensation can be also
observed. The cell surface fibrilar structure which constitutes
polysaccharide component of the cell wall capsule was also
disrupted (Pavel and Vasile, 2012). These features collectively
suggest that triclosan-treated C. neoformans demonstrated
apoptotic-like cell death (ALCD) mechanism.
To further confirm if triclosan triggers apoptosis in
C. neoformans cells, we analyzed the cells using TUNEL
apoptosis assay followed by flow cytometrical analysis (Figure 4).
DNA fragmentation (one of the hallmark of apoptosis) generates
free 3′-hydroxyl residues that can be utilized by terminal
deoxynucleotidyl transferase to incorporate FITC-tagged dUTP
FIGURE 3 | Cell morphology of triclosan-treated C. neoformans. Electron microscopic pictures of C. neoformans with or without exposure to triclosan
(0.5 µg/ml) for 2 h. (A,B) Untreated control cells showed intact nucleus and cytoplasm. (C–F) Triclosan-treated C. neoformans showed apoptotic morphologies.
Note the appearance of apoptotic features such as mitochondrial swelling (arrow) and nuclear chromatin condensation (broken arrow). Besides, intense cytoplasmic
vacuolations were formed in the cells. Cell surface fibrilar structures which form capsule polysaccharide component were also disrupted (Pavel and Vasile, 2012).
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into the blunt ends of double-stranded DNA break. Our data
showed that 90.7% triclosan-treated C. neoformans H99 cells
were apoptotic (FITC-positive) compared to only 2.1% in the
untreated control. Around 71.4% of apoptotic cells were detected
in the positive control (H2O2-treated cells). Therefore, triclosan
can inhibit C. neoformans by inducing ALCD.
DISCUSSION
Our study demonstrated the potent antifungal effect of triclosan
against C. neoformans. In fact, triclosan treatment exerted
a stronger growth inhibition in C. neoformans compared to
C. albicans, as evidenced by comparatively lower MIC-1 values
(ranged from 0.25 to 3.80 µg/ml) in C. neoformans strains tested,
compared to MIC-1 values in C. albicans (ranged from 59.6 to
>64 µg/ml).
Combined antibiotic therapy can delay the emergence of
microbial resistance by producing desirable synergistic effects
in the infection treatment (Adwan and Mhanna, 2008). In our
study, synergism between triclosan and two standard drugs
(amphotericin B and fluconazole) was established. Fluconazole
and amphotericin B are commonly used drugs for candidiasis
and cryptococcal diseases. Fluconazole is a member of the
azole family that targets the Erg11 enzyme (an essential fungal
cytochrome P450 lanosterol 14α-demethylase), thus inhibiting
ergosterol biosynthesis (Rodero et al., 2003; Heilmann et al.,
2010). Amphotericin B, on the other hand, binds directly
to ergosterol and kills yeast cells via ion channel-mediated
plasma membrane permeabilization (Gruda and Dussault, 1988).
Combinational treatment of triclosan and other drugs has been
shown to significantly enhance the drug efficacy against bacteria
(Tambe et al., 2001; Sharma et al., 2003). However, two previous
reports using C. albicans demonstrated opposing results for
combinational usage of triclosan plus fluconazole, whereby one
showed synergistic effect (Yu et al., 2011) and another showed
antagonistic effect (Higgins et al., 2012). In C. neoformans, we
reported that triclosan acts in synergy with fluconazole and
amphotericin B.
Administration of standard fungal drugs in AIDS-associated
cryptococcal meningoencephalitis shows a successful rate of
34% (fluconazole) in 40% in fluconazole and amphotericin B
recipients (Saag et al., 1992). Furthermore, amphotericin B
treatment frequently results in adverse effect (nephrotoxicity)
in cryptococcal meningitis patients (Perfect et al., 2010), which
suggests the need for a more effective treatment strategy. Perhaps
a combinational therapy with triclosan could be a good solution.
As far as safety is concerned, triclosan is considered non-
carcinogenic with low indication of toxicity in both animal and
human studies (Bhargava and Leonard, 1996). Triclosan has been
impregnated to many of the daily contact products including
soaps, toothpastes, disinfection solutions, and medical devices.
Upon usage, triclosan can penetrate through cutaneous layer
into the blood stream and excreted in the urine or feces (Moss
et al., 2000; Sandborgh-Englund et al., 2006). Wound closure with
triclosan-coated sutures has been shown to reduce the risk of
infection after cerebrospinal fluid surgery (Rozzelle et al., 2008).
FIGURE 4 | TUNEL assay. Apoptosis of triclosan-treated C. neoformans H99
cells was determined by TUNEL assay followed by flow cytometry analysis.
C. neoformans H99 cells were non-treated (control), treated with triclosan
(0.5 µg/ml) or H2O2 (2 mM) for 4 h. Percentages of the apoptotic cells were
indicated. Data shown are representative of two independent experiments.
Triclosan administration also significantly reduced bacterial level
in experimental gingivitis (Pancer et al., 2016) and nosocomial
infection (Webster et al., 1994).
The mechanism of triclosan-mediated cell disruption has been
described in different pathogens. Triclosan triggers changes in
bacteria membrane fluidity and function at lower concentration,
and leads to cell lysis at a higher concentration (Gomez
Escalada et al., 2005). It is also known to block lipid synthesis
primarily by targeting the carrier protein of the bacterial type
II fatty acid synthesis (FASII) pathway (McMurry et al., 1998).
Contradictory, a recent study shows that Fas1 and Fas2 gene
overexpression did not alter fungal susceptibility to triclosan and
suggests that there may be an alternative target of triclosan in
addition to the lipid synthesis pathway (Higgins et al., 2012).
Therefore, further investigations are required to elucidate the
actual mechanism of action. In mammals, triclosan antagonizes
estrogen or androgen receptors, elevates resting cytosolic Ca2+
in primary skeletal myotubules (Ahn et al., 2008) and impairs the
excitation contraction coupling of cardiac and skeletal function
(Cherednichenko et al., 2012).
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From electron microscope pictures, we hypothesize that
triclosan induces ALCD, a program cell death mechanism in
C. neoformans because various apoptosic subcellular changes
can be visualized as early as 2 h post treatment. At an early
stage of an apoptotic cell, cell shrinkage occurs as a result
of organelle condensation and decreased cytoplasm density
(Häcker, 2000). During the apoptosis process, free radicals
can modify mitochondrial membrane potential thus inducing
mitochondrial swelling and fusion of adjacent mitochondria into
megamitochondria (Wakabayashi, 1999). Mitochondria release
cytochrome c from storage which subsequently activates the
caspase cascade leading to nuclear cleavage (Zhang and Xu,
2000) and extensive plasma membrane blebbing (Coleman et al.,
2001). We reported some apoptotic features in triclosan-treated
C. neoformans cells including condensed nuclear chromatin,
DNA fragmentation and mitochondrial swelling. Whether the
H2O2 treatment induces similar pattern of apoptotic features
in C. neoformans remains to be investigated. We suspected that
the intensive cytoplasmic vacuolation was due to the decreased
cytoplasm density and organelles condensation although the cell
structure remained intact as a resultant of rigid fungal cell wall.
Several pathogenic fungi have been reported to undergo ALCD
(Buttner et al., 2006; Ramsdale, 2008; Sharon et al., 2009). For
instance, mutation of CDC48 in Saccharomyces cerevisiae shows
apoptosis characteristic including chromatin condensation and
fragmentation (Madeo et al., 1997). Interestingly, overexpression
of mammalian anti-apoptotic Bcl2 rescues fungal cell apoptosis
(Longo et al., 1997) while overexpression of pro-apoptotic Bax
enhances the cell death effect (Manon et al., 1997; Ligr et al.,
1998). ALCD has also been reported in C. neoformans when the
cells were stimulated with hydrogen peroxide or cultured in the
presence of Staphylococcus aureus (Ikeda and Sawamura, 2008).
The apoptosis pathway in C. neoformans is controlled through
regulation of apoptosis-inducing factor (Aif1) and metacaspases
(Mca1 and Mca2) (Semighini et al., 2011).
TUNEL assay takes advantage of in situ labeling technology,
which uses TdT to incorporate FITC-tagged dUTP into
blunt ends of double stranded DNA breaks (Denton and
Kumar, 2015). TUNEL-labeled cells indicate nuclear DNA
fragmentation, an irreversible step in apoptosis (Lawry, 2004).
During infection, C. neoformans is able to cause apoptotic
cell death of mammalian cells. In the experimental animals
with disseminated cryptococcosis, a major constituent of
C. neoformans capsular polysaccharide, glucuronoxylomannan
(GXM) results in increased TUNEL-labeled cells in both lung
and spleen (Chiapello et al., 2003). Studies also show that
C. neoformans induces cell death in rat macrophages by
promoting inducible nitric oxide synthase expression with nitric
oxide production in rat macrophages (Chiapello et al., 2008;
Villena et al., 2008) besides interrupting the lysosome and
phagosome maturation (Davis et al., 2015; Smith et al., 2015).
In addition, C. neoformans induces apoptosis of T lymphocytes
through activation of caspase-8 that initiates DNA cleavage
activity (Pericolini et al., 2006).
In summary, our study reveals a strong inhibitory effect
of triclosan as well as its synergy with amphotericin B and
fluconazole in blocking cell growth of the pathogenic fungus
C. neoformans. We also report that triclosan maybe fungicidal
by inducing the ALCD mechanism in C. neoformans. Our study
reveals a potential therapeutic value of triclosan as a novel drug
or a synergent in the treatment of cryptococcal infection.
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